Zai Lab and Novocure Report P-III Trial (LUNAR) Results of Tumor Treating Fields Therapy for Metastatic Non-Small Cell Lung Cancer
Shots:
- The P-III trial evaluating TTFields therapy + ICI or docetaxel vs ICI or docetaxel alone. The trial met its 1EPs & showed a 3mos. improvement in m-OS (13.2 vs 9.9mos.) in patients with TTFields therapy + standard therapies, profound OS benefit in the ICI subgroup
- m-OS (18.5 vs 10.8mos.) in patients with TTFields therapy and ICI; 11.1mos. in TTFields therapy & docetaxel vs 8.7mos. in docetaxel alone, was well-tolerated with no added systemic toxicities and few grade 3 device-related AEs
- Baseline characteristics were well balanced b/w cohorts, 1yr. & 3yr. survival rates in TTFields therapy + standard therapies (53% vs 42%) & (18% vs 7%); m-PFS (4.8 vs 4.1mos.). Based on the P-III trial results, the PMA submission to the US FDA is expected in H2’23
Ref: Globenewswire | Image: Zai Lab
Related News:- Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
